PFO
BBH icon

Pathstone Family Office’s VanEck Biotech ETF BBH Stock Holding History

Pathstone Family Office’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-180
Closed -$16K – 192
2013
Q4 		$16K Buy
+180
New +$15.1K 0.03% 111

Other funds holding BBH

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NCM
Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
LFM
Lumina Fund Management New York $164M AUM 27.72% 1-Year Est. Return
AHS
Aspiriant Holdings S3 Los Angeles, California $233M AUM 3.13% 1-Year Est. Return

Pathstone Family Office's BBH Position: Q1 2014 in Review

Pathstone Family Office sold out of VanEck Biotech ETF (BBH) in Q1 2014, closing a stake of 180 shares — an estimated $16K sold.

Pathstone Family Office first reported a position in BBH in Q4 2013 and held it in 1 quarter. The position peaked at $16K in Q4 2013. 59 funds tracked by Wall St. Rank hold BBH as of Q1 2014.

  • Pathstone Family Office reported no remaining VanEck Biotech ETF position as of Q1 2014 after selling out during the quarter.
  • Pathstone Family Office sold 180 VanEck Biotech ETF shares in Q1 2014, an estimated $16K.
  • Pathstone Family Office first reported a position in VanEck Biotech ETF in Q4 2013 and held it in 1 quarter.
  • Pathstone Family Office's VanEck Biotech ETF position peaked at $16K in Q4 2013.
  • 59 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2014.

Based on Pathstone Family Office's 13F filing for Q1 2014, filed 7 May 2014.